Analyst Price Target is C$4.67
▲ +∞ Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Evogene in the last 3 months. The average price target is C$4.67, with a high forecast of C$6.00 and a low forecast of C$4.00. The average price target represents a ∞ upside from the last price of C$0.00.
Current Consensus is
Buy
The current consensus among 2 investment analysts is to buy stock in Evogene. This Buy consensus rating has held steady for over two years.
Evogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., seed traits through the Ag-Seeds division, and ag-solutions for castor oil production through Casterra Ltd.
Read More